DDInter576 DDInter448
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) downregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) downregulates {v} (Gene) DNMT1
DNMT1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Disulfiram {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Crizotinib
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Disulfiram (Compound) downregulates ERBB3 (Gene) and ERBB3 (Gene) is upregulated by Crizotinib (Compound)
Disulfiram (Compound) downregulates DNMT1 (Gene) and DNMT1 (Gene) is downregulated by Crizotinib (Compound)
Disulfiram (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Crizotinib (Compound)
Disulfiram (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Disulfiram (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates CDK7 (Gene) and CDK7 (Gene) is bound by Crizotinib (Compound)
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Crizotinib (Compound)
Disulfiram (Compound) upregulates RELB (Gene) and RELB (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)